Physician profile
Stephen A Graham
NPI 1841228640
$832.14
in general payments reported to CMS, 2019-2025
21 companies · $35.73 in 2025
The $35.73 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $74.32 · 2021: $160 · 2022: $146 · 2023: $118 · 2024: $299 · 2025: $35.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $124.88 | 2022-2024 | Vyepti |
| Amgen INC. | $97.98 | 2020-2021 | |
| Boston Scientific Corporation | $97.72 | 2022 | |
| Sumitomo Pharma America, INC. | $50.28 | 2023-2024 | Gemtesa |
| Pacira Pharmaceuticals Incorporated | $47.99 | 2024-2025 | Exparel, Zilretta, Iovera |
| Ucb, INC. | $46.64 | 2021-2024 | Briviact |
| Sk Life Science, INC. | $40.49 | 2020-2021 | |
| Abbott Laboratories | $38.83 | 2021 | |
| Scilex Pharmaceuticals INC. | $36.79 | 2024-2025 | |
| Emd Serono, INC. | $34.98 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $25.37 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.32 | 2024 | Ultomiris |
| Aucta Pharmaceuticals, INC. | $24.29 | 2024 | Motpoly Xr |
| Lilly USA, LLC | $23.88 | 2024 | Emgality |
| Merz Pharmaceuticals, LLC | $23.51 | 2023 | Xeomin |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $19.46 | 2024 | Belbuca |
| Phadia US INC. | $17.09 | 2024 | Immunocap |
| Csl Behring | $16.08 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.38 | 2024 | Horizant |
| Neurelis, INC. | $13.18 | 2021 | |
| Axsome Therapeutics, INC. | $13.00 | 2023 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.